-
A human-mouse atlas of intrarenal myeloid cells identifies conserved disease-associated macrophages in lupus nephritis. J Exp Med. 2025 Nov 03; 222(11). Hoover PJ, Raparia C, Lieb DJ, Tzur Y, Kang J, Arazi A, Leavitt R, Mishra R, Shah SI, Simmons D, Li S, Peters M, Eisenhaure T, Few-Cooper TJ, Gurajala SS, Sonny A, Hodgin JB, Berthier CC, Guthridge JM, Fava A, Clancy RM, Putterman C, Izmirly PM, Belmont HM, Kalunian K, Kamen D, Wofsy D, Buyon JP, James JA, Petri M, Diamond B, Raychaudhuri S, Shen-Orr SS, Accelerating Medicines Partnership in RA/SLE network, Hacohen N, Davidson A. PMID: 40900124; PMCID: PMC12928530.
-
Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell-Targeting Treatment in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2025 Nov; 77(11):1560-1572. van Dooren HJ, van Schaik M, Dorjée AL, Arends EJ, Mackay M, Cooney L, Fox DA, Wofsy D, Smilek D, Aranow C, Dall'Era M, Huizinga TWJ, van Kooten C, Toes REM, Diamond B, Teng YKO, Suurmond J. PMID: 40356198; PMCID: PMC12353765.
-
Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. J Clin Invest. 2025 Aug 15; 135(16). Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, Guthridge J, Hoover PJ, Dall'Era M, Wofsy D, Kamen DL, Kalunian KC, Furie R, Belmont M, Izmirly P, Clancy R, Hildeman D, Woodle ES, Apruzzese W, McMahon MA, Grossman J, Barnas JL, Payan-Schober F, Ishimori M, Weisman M, Kretzler M, Berthier CC, Hodgin JB, Demeke DS, Putterman C, Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE, Brenner MB, Anolik JH, Raychaudhuri S, Hacohen N, James JA, Davidson A, Petri MA, Buyon JP, Diamond B, Zhang F, Lederer JA, Rao DA. PMID: 40536813; PMCID: PMC12352894.
-
Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis. Rheumatology (Oxford). 2025 May 01; 64(5):2676-2687. Chu D, Schwartz N, Ampudia J, Guthridge J, James J, Buyon JP, Connelly S, Fung M, Ng CT, Accelerating Medicines Partnership: RA/SLE Network , Fava A, Petri M, Mohan C, Putterman C. PMID: 39404817; PMCID: PMC12048083.
-
Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study. Rheumatology (Oxford). 2025 May 01; 64(5):2731-2740. Anders HJ, Chan TM, Sanchez-Guerrero J, Wofsy D, Bensley K, Kim L, Lo KH, Shu C, Shao J, Karyekar CS, Diamond B. PMID: 39673415; PMCID: PMC12048075.
-
Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network. Rheumatology (Oxford). 2025 Mar 01; 64(3):1193-1200. Carlucci PM, Preisinger K, Deonaraine KK, Zaminski D, Dall'Era M, Gold HT, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Furie R, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao D, Weisman MH, Izmirly PM, Buyon J, Petri M, Accelerating Medicines Partnership in RA/SLE Network . PMID: 38530774; PMCID: PMC11879353.
-
Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. bioRxiv. 2024 Mar 09. Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, Guthridge J, Hoover PJ, Dall'Era M, Wofsy D, Kamen DL, Kalunian KC, Furie R, Belmont M, Izmirly P, Clancy R, Hildeman D, Woodle ES, Apruzzese W, McMahon MA, Grossman J, Barnas JL, Payan-Schober F, Ishimori M, Weisman M, Kretzler M, Berthier CC, Hodgin JB, Demeke DS, Putterman C, Accelerating Medicines Partnership: RA/SLE Network, Brenner MB, Anolik JH, Raychaudhuri S, Hacohen N, James JA, Davidson A, Petri MA, Buyon JP, Diamond B, Zhang F, Lederer JA, Rao DA. PMID: 38293222; PMCID: PMC10827101.
-
Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network. Arthritis Res Ther. 2024 02 20; 26(1):54. Izmirly PM, Kim MY, Carlucci PM, Preisinger K, Cohen BZ, Deonaraine K, Zaminski D, Dall'Era M, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao DA, Weisman MH, Accelerating Medicines Partnership in RA/SLE Network, Petri M, Buyon J, Furie R. PMID: 38378664; PMCID: PMC10877793.
-
Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight. 2024 01 23; 9(2). Fava A, Buyon J, Magder L, Hodgin J, Rosenberg A, Demeke DS, Rao DA, Arazi A, Celia AI, Putterman C, Anolik JH, Barnas J, Dall'Era M, Wofsy D, Furie R, Kamen D, Kalunian K, James JA, Guthridge J, Atta MG, Monroy Trujillo J, Fine D, Clancy R, Belmont HM, Izmirly P, Apruzzese W, Goldman D, Berthier CC, Hoover P, Hacohen N, Raychaudhuri S, Davidson A, Diamond B, Accelerating Medicines Partnership in RA/SLE network, Petri M. PMID: 38258904; PMCID: PMC10906224.
-
High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology (Oxford). 2022 11 02; 61(11):4335-4343. Carlucci PM, Li J, Fava A, Deonaraine KK, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, DeJager W, Guthridge JM, Haag K, Rao DA, Brenner MB, Lederer JA, Apruzzese W, Belmont HM, Izmirly PM, Zaminski D, Wu M, Connery S, Payan-Schober F, Furie R, Dall'Era M, Cho K, Kamen D, Kalunian K, Anolik J, Barnas J, Ishimori M, Weisman MH, Accelerating Medicines Partnership (AMP) RA/SLE Network, Buyon JP, Petri M. PMID: 35212719; PMCID: PMC9629353.
-
Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. Arthritis Rheumatol. 2022 05; 74(5):829-839. Fava A, Rao DA, Mohan C, Zhang T, Rosenberg A, Fenaroli P, Belmont HM, Izmirly P, Clancy R, Trujillo JM, Fine D, Arazi A, Berthier CC, Davidson A, James JA, Diamond B, Hacohen N, Wofsy D, Raychaudhuri S, Apruzzese W, Accelerating Medicines Partnership in Rheumatoid Arthritis and Systemic Lupus Erythematosus Network, Buyon J, Petri M. PMID: 34783463; PMCID: PMC9050800.
-
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus Sci Med. 2021 08; 8(1). Deonaraine KK, Carlucci PM, Fava A, Li J, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, Haag K, Rao DA, Apruzzese W, Belmont HM, Izmirly PM, Wu M, Connery S, Payan-Schober F, Furie RA, Berthier CC, Dall'Era M, Cho K, Kamen DL, Kalunian K, Anolik J, Ishimori M, Weisman MH, Accelerating Medicines Partnership RA/SLE network, Petri MA, Buyon JP. PMID: 34389634; PMCID: PMC8354250.
-
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Ann Rheum Dis. 2021 06; 80(6):775-781. Aringer M, Brinks R, Dörner T, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Schmajuk G, Tani C, Tedeschi SK, Touma Z, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Costenbader K, Johnson SR. PMID: 33568386.
-
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol. 2021 01; 73(1):121-131. Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon M, Parikh SV, Pendergraft WF, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. PMID: 32755035; PMCID: PMC7839443.
-
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Ann Rheum Dis. 2020 10; 79(10):1333-1339. Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger WB, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Aringer M. PMID: 32816709.
-
A Tale of Two Trials. Arthritis Rheumatol. 2020 08; 72(8):1256-1257. Wofsy D. PMID: 32182394.
-
Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritis. JCI Insight. 2020 06 18; 5(12). Fava A, Buyon J, Mohan C, Zhang T, Belmont HM, Izmirly P, Clancy R, Trujillo JM, Fine D, Zhang Y, Magder L, Rao DA, Arazi A, Berthier CC, Davidson A, Diamond B, Hacohen N, Wofsy D, Apruzzese W, Accelerating Medicines Partnership in SLE network, Raychaudhuri S, Petri M. PMID: 32396533; PMCID: PMC7406291.
-
The Validity of Scores From the New MCAT Exam in Predicting Student Performance: Results From a Multisite Study. Acad Med. 2020 03; 95(3):387-395. Busche K, Elks ML, Hanson JT, Jackson-Williams L, Manuel RS, Parsons WL, Wofsy D, Yuan K. PMID: 31425189.
-
Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care Res (Hoboken). 2020 02; 72(2):233-242. Hoover P, Der E, Berthier CC, Arazi A, Lederer JA, James JA, Buyon J, Petri M, Belmont HM, Izmirly P, Wofsy D, Hacohen N, Diamond B, Putterman C, Davidson A. PMID: 31502417; PMCID: PMC6992476.
-
The Relationships among Self-Designated Disadvantage, Socioeconomic Disadvantage, and Academic Performance in Medical School: A Multi-Institutional Study. J Health Care Poor Underserved. 2020; 31(4S):208-222. Henderson MC, Jerant A, Unkart J, Griffin EJ, Sciolla SF, Kelly CJ, Peterson EM, Hall T, Wofsy D, Fancher TL. PMID: 35061622.
-
Georgia Abortion Law and Our Commitment to Patients. Arthritis Rheumatol. 2020 02; 72(2):377-378. Craft JE, Crow MK, Lockshin MD, Salmon JE, Diamond B, Elkon KB, Flood J, Fox DA, Gabriel SE, Gilkeson GS, Hahn BH, Hardin J, Koopman WJ, Seaman WE, Wofsy D, Sergent JS, Uknis AB, Weinblatt ME. PMID: 31637878.
-
Design and application of single-cell RNA sequencing to study kidney immune cells in lupus nephritis. Nat Rev Nephrol. 2020 04; 16(4):238-250. Rao DA, Arazi A, Wofsy D, Diamond B. PMID: 31853010; PMCID: PMC7251304.
-
PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight. 2019 10 17; 4(20). Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G, Muise ES, Zhang KX, Arazi A, Keras G, Li ZJ, Qu Y, Gurish MF, Petri M, Buyon JP, Putterman C, Wofsy D, James JA, Guthridge JM, Diamond B, Anolik JH, Mackey MF, Alves SE, Nigrovic PA, Costenbader KH, Brenner MB, Lederer JA, Rao DA, Accelerating Medicines Partnership (AMP) RA/SLE Network. PMID: 31536480; PMCID: PMC6824311.
-
Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019 Oct; 20(10):1404. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B, Accelerating Medicines Partnership in SLE network. PMID: 31409923.
-
Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. Rheumatol Adv Pract. 2019; 3(2):rkz021. Gordon C, Bassi R, Chang P, Kao A, Jayne D, Wofsy D, Fleuranceau-Morel P. PMID: 31528843; PMCID: PMC6735746.
-
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 09; 71(9):1400-1412. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. PMID: 31385462; PMCID: PMC6827566.
-
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019 09; 78(9):1151-1159. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. PMID: 31383717.
-
The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019 07; 20(7):902-914. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B, Accelerating Medicines Partnership in SLE network. PMID: 31209404; PMCID: PMC6726437.
-
Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019 05; 78(5):634-640. Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. PMID: 30692164; PMCID: PMC7057251.
-
Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 03; 71(3):431-440. Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD, Autoimmunity Centers of Excellence. PMID: 30277008; PMCID: PMC6447289.
-
Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. J Rheumatol. 2019 07; 46(7):721-726. Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M. PMID: 30554156.
-
Do Multiple Mini-Interview and Traditional Interview Scores Differ in Their Associations With Acceptance Offers Within and Across Five California Medical Schools? Acad Med. 2018 08; 93(8):1227-1233. Jerant A, Henderson MC, Griffin E, Hall TR, Kelly CJ, Peterson EM, Wofsy D, Franks P. PMID: 29561273.
-
Medical School Applicant Characteristics Associated With Performance in Multiple Mini-Interviews Versus Traditional Interviews: A Multi-Institutional Study. Acad Med. 2018 07; 93(7):1029-1034. Henderson MC, Kelly CJ, Griffin E, Hall TR, Jerant A, Peterson EM, Rainwater JA, Sousa FJ, Wofsy D, Franks P. PMID: 29095170.
-
Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis. Kidney Int Rep. 2018 Sep; 3(5):1057-1063. Shidham G, Ayoub I, Birmingham D, Hebert P, Rovin B, Diamond B, Wofsy D, Hebert L. PMID: 30197972; PMCID: PMC6127448.
-
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889. Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. PMID: 29563108.
-
Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. Arthritis Care Res (Hoboken). 2018 04; 70(4):571-581. Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. PMID: 28692774; PMCID: PMC5996759.
-
Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis. Lupus Sci Med. 2017; 4(1):e000229. Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D. PMID: 29214037; PMCID: PMC5704742.
-
Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Arthritis Rheumatol. 2017 01; 69(1):122-130. Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. PMID: 27390168; PMCID: PMC6681010.
-
In memoriam: Ephraim P. Engleman, MD, 1911-2015. Arthritis Rheumatol. 2015 Nov; 67(11):2795-6. Wofsy D. PMID: 26508466.
-
Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med. 2015; 2(1):e000089. Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D. PMID: 26023331; PMCID: PMC4442174.
-
Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America. Arthritis Rheumatol. 2015 May; 67(5):1144-6. Wofsy D, Diamond B, Houssiau FA. PMID: 25779381; PMCID: PMC4523131.
-
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015 Nov; 74(11):2006-15. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. PMID: 24951103; PMCID: PMC4680140.
-
Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum. 2013 Jun; 65(6):1586-91. Wofsy D, Hillson JL, Diamond B. PMID: 23529285; PMCID: PMC4398144.
-
Recent progress in conventional and biologic therapy for systemic lupus erythematosus. Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii66-8. Wofsy D. PMID: 23253930.
-
Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012 Nov; 64(11):3660-5. Wofsy D, Hillson JL, Diamond B. PMID: 22806274.
-
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17; 365(20):1886-95. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N, ALMS Group. PMID: 22087680.
-
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011 May; 38(5):846-54. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE. PMID: 21285160.
-
Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011 Mar; 63(3):351-7. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. PMID: 21080348.
-
Plagiarism on personal statements: a disturbing symptom of a broader trend. Ann Intern Med. 2010 Jul 20; 153(2):128-9. Papadakis MA, Wofsy D. PMID: 20643994.
-
Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Nat Rev Rheumatol. 2010 Mar; 6(3):124-5. Dall'Era M, Wofsy D. PMID: 20197774.
-
Biologic therapy for systemic lupus erythematosus. Discov Med. 2010 Jan; 9(44):20-3. Dall'Era M, Wofsy D. PMID: 20102681.
-
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010 Jan; 62(1):211-21. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA, ALMS Group. PMID: 20039429.
-
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010 Jan; 49(1):128-40. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N. PMID: 19933596; PMCID: PMC2789586.
-
Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009 Oct; 5(10):560-5. Esensten JH, Wofsy D, Bluestone JA. PMID: 19798031; PMCID: PMC3086064.
-
Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol. 2009 Jun; 5(6):348-51. Dall'Era M, Wofsy D. PMID: 19491915.
-
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May; 20(5):1103-12. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus Management Study Group. PMID: 19369404; PMCID: PMC2678035.
-
Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009 Apr 01; 301(13):1367-72. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH, Thomson GE, Wofsy D. PMID: 19336712.
-
A quality indicator set for systemic lupus erythematosus. Arthritis Rheum. 2009 Mar 15; 61(3):370-7. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E, Systemic Lupus Erythematosus Quality Indicators Project Expert Panels. PMID: 19248127; PMCID: PMC2748348.
-
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec; 56(12):4142-50. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. PMID: 18050206.
-
Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus. 2007; 16(12):972-80. Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N. PMID: 18042591.
-
Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol. 2006 Sep; 18(5):476-80. Dall'Era M, Wofsy D. PMID: 16896285.
-
Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases. Arthritis Rheum. 2006 Apr 15; 55(2):322-4. Daikh DI, Gillis J, Wofsy D. PMID: 16583382.
-
Living in a different world. Arthritis Rheum. 2005 Feb; 52(2):395-401. Wofsy D. PMID: 15692996.
-
Block and tackle: CTLA4Ig takes on lupus. Lupus. 2005; 14(3):197-203. Davidson A, Diamond B, Wofsy D, Daikh D. PMID: 15807196.
-
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec; 46(12):3251-8. Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group. PMID: 12483729.
-
Treatment of autoimmune diseases by inhibition of T-cell costimulation. Mod Rheumatol. 2002 Mar; 12(1):1-4. Wofsy D, Daikh DI. PMID: 24383824.
-
The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic. Arthritis Rheum. 2001 Aug; 44(8):1730-5. Diamond B, Bluestone J, Wofsy D. PMID: 11508422.
-
Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001 Mar 01; 166(5):2913-6. Daikh DI, Wofsy D. PMID: 11207238.
-
Nephritogenic cytokines and disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets. Kidney Int. 2001 Feb; 59(2):565-78. Wada T, Schwarting A, Chesnutt MS, Wofsy D, Rubin Kelley V. PMID: 11168938.
-
Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001 Jan; 28(1):95-101. Davis JC, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. PMID: 11196549.
-
Treatment of autoimmunity by inhibition of T cell costimulation. Adv Exp Med Biol. 2001; 490:113-7. Daikh DI, Wofsy D. PMID: 11505969.
-
The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G. Immunology. 1999 Nov; 98(3):475-80. Jeddi P, Keusch J, Lydyard PM, Bodman-Smith KB, Chesnutt MS, Wofsy D, Hirota H, Taga T, Delves PJ. PMID: 10583610; PMCID: PMC2326953.
-
Effects of anti-B7 monoclonal antibodies on humoral immune responses. J Autoimmun. 1999 Mar; 12(2):101-8. Daikh DI, Wofsy D. PMID: 10047430.
-
On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases. Transplant Proc. 1998 Dec; 30(8):4027-8. Daikh DI, Wofsy D. PMID: 9865285.
-
Opportunities for future biological therapy in SLE. Baillieres Clin Rheumatol. 1998 Aug; 12(3):529-41. Wofsy D, Daikh DI. PMID: 9890111.
-
Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice. Clin Immunol Immunopathol. 1998 Apr; 87(1):23-32. Chesnutt MS, Finck BK, Killeen N, Connolly MK, Goodman H, Wofsy D. PMID: 9576007.
-
Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997 Oct 01; 159(7):3104-8. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. PMID: 9317105.
-
The CD28-B7 costimulatory pathway and its role in autoimmune disease. J Leukoc Biol. 1997 Aug; 62(2):156-62. Daikh D, Wofsy D, Imboden JB. PMID: 9261329.
-
Blind T-cell homeostasis in CD4-deficient mice. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 01; 11(4):334-40. Adleman LM, Wofsy D. PMID: 8601219.
-
Treatment of murine lupus with CTLA4Ig. Science. 1994 Aug 26; 265(5176):1225-7. Finck BK, Linsley PS, Wofsy D. PMID: 7520604.
-
Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 1994 Aug; 94(2):585-91. Finck BK, Chan B, Wofsy D. PMID: 8040314; PMCID: PMC296134.
-
Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy. Clin Immunol Immunopathol. 1994 Aug; 72(2):198-203. Connolly MK, Kitchens EA, Chan B, Jardieu P, Wofsy D. PMID: 8050193.
-
Recent advances in the treatment of rheumatic diseases: new approaches to immunotherapy. Ryumachi. 1994 Apr; 34(2):164-5. Wofsy D. PMID: 8202830.
-
T-cell homeostasis: implications in HIV infection . J Acquir Immune Defic Syndr (1988). 1993 Feb; 6(2):144-52. Adleman LM, Wofsy D. PMID: 8094457.
-
Treatment of murine lupus with anti-CD4 monoclonal antibodies. Immunol Ser. 1993; 59:221-36. Wofsy D. PMID: 8096400.
-
The role of T-cell subsets in the response to anti-CD3 monoclonal antibodies. Clin Immunol Immunopathol. 1992 Dec; 65(3):234-41. Finck BK, Yung CM, Carteron NL, Wofsy D. PMID: 1360341.
-
Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. J Immunol. 1992 Nov 01; 149(9):3083-8. Connolly K, Roubinian JR, Wofsy D. PMID: 1357036.
-
CD4 antibody therapy in systemic lupus erythematosus. Semin Immunol. 1990 Nov; 2(6):419-25. Wofsy D, Carteron NL. PMID: 2104279.
-
F(ab')2 anti-CD4 and intact anti-CD4 monoclonal antibodies inhibit the accumulation of CD4+ T cells, CD8+ T cells, and B cells in the kidneys of lupus-prone NZB/NZW mice. Clin Immunol Immunopathol. 1990 Sep; 56(3):373-83. Carteron NL, Wofsy D, Schimenti C, Ermak TH. PMID: 1975226.
-
Regulation of immunity by anti-T-cell antibodies. West J Med. 1990 Sep; 153(3):265-8. Wofsy D. PMID: 2219889; PMCID: PMC1002527.
-
Effects of recombinant murine tumor necrosis factor-alpha on immune function. J Immunol. 1990 Mar 01; 144(5):1753-8. Gordon C, Wofsy D. PMID: 2307839.
-
Treatment of murine lupus with monoclonal antibody to L3T4. II. Effects on immunohistopathology of thymus, spleen, and lymph node. Lab Invest. 1989 Oct; 61(4):447-56. Ermak TH, Steger HJ, Wofsy D. PMID: 2529396.
-
Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989 Sep; 52(3):421-34. Gordon C, Ranges GE, Greenspan JS, Wofsy D. PMID: 2758698.
-
Effects of selective depletion of L3T4+ T-lymphocytes on herpes simplex virus encephalitis. Clin Immunol Immunopathol. 1989 Aug; 52(2):190-201. Erlich KS, Wofsy D, Dix RD, Mills J. PMID: 2525439.
-
Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. J Immunol. 1989 Mar 01; 142(5):1470-5. Carteron NL, Schimenti CL, Wofsy D. PMID: 2521880.
-
New therapies for the rheumatic diseases. Bull Rheum Dis. 1989; 38(4):1-8. Klippel JH, Strober S, Wofsy D. PMID: 2670022.
-
Treatment of murine lupus with monoclonal antibody to L3T4. I. Effects on the distribution and function of lymphocyte subsets and on the histopathology of autoimmune disease. J Autoimmun. 1988 Oct; 1(5):415-31. Wofsy D, Chiang NY, Greenspan JS, Ermak TH. PMID: 3267085.
-
The role of Lyt-2+ T cells in the regulation of autoimmunity in murine lupus. J Autoimmun. 1988 Apr; 1(2):207-17. Wofsy D. PMID: 2978113.
-
Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J Immunol. 1988 Feb 01; 140(3):713-6. Carteron NL, Wofsy D, Seaman WE. PMID: 2448372.
-
Selective manipulation of the immune response in vivo by monoclonal antibodies. Annu Rev Med. 1988; 39:231-41. Seaman WE, Wofsy D. PMID: 3285774.
-
Treatment of autoimmune diseases with monoclonal antibodies. Prog Allergy. 1988; 45:106-20. Wofsy D. PMID: 3064092.
-
New approaches to treating systemic lupus erythematosus. West J Med. 1987 Aug; 147(2):181-6. Wofsy D. PMID: 3310402; PMCID: PMC1025772.
-
Proliferation of Ly-1 B cells in autoimmune NZB and (NZB x NZW)F1 mice. Eur J Immunol. 1987 Jun; 17(6):809-14. Wofsy D, Chiang NY. PMID: 2954827.
-
Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol. 1987 May 15; 138(10):3247-53. Wofsy D, Seaman WE. PMID: 3106478.
-
Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells. J Immunol. 1986 Dec 01; 137(11):3414-9. Gutstein NL, Wofsy D. PMID: 3097122.
-
Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells. Transplantation. 1986 Dec; 42(6):636-42. Woodcock J, Wofsy D, Eriksson E, Scott JH, Seaman WE. PMID: 2947360.
-
Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol. 1986 Aug 15; 137(4):1127-32. Gutstein NL, Seaman WE, Scott JH, Wofsy D. PMID: 3090139.
-
Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. J Immunol. 1986 Jun 15; 136(12):4554-60. Wofsy D. PMID: 3086436.
-
Anti-Ly-1 antibody induces interleukin 2 release from T cells. J Immunol. 1986 Mar 01; 136(5):1734-7. Stanton T, Stevens TL, Ledbetter JA, Wofsy D. PMID: 3081630.
-
Analysis of the function of L3T4+ T cells by in vivo treatment with monoclonal antibody to L3T4. Immunol Res. 1986; 5(2):97-105. Wofsy D, Seaman WE. PMID: 3093610.
-
Strategies for treating autoimmune disease with monoclonal antibodies. West J Med. 1985 Dec; 143(6):804-9. Wofsy D. PMID: 3911593; PMCID: PMC1306490.
-
Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol. 1985 Oct; 135(4):2331-6. Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P. PMID: 3928743.
-
Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice. J Immunol. 1985 Sep; 135(3):1698-701. Wofsy D, Mayes DC, Woodcock J, Seaman WE. PMID: 3160776.
-
Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 01; 161(2):378-91. Wofsy D, Seaman WE. PMID: 3919141; PMCID: PMC2187572.
-
Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol. 1985 Feb; 134(2):852-7. Wofsy D, Ledbetter JA, Hendler PL, Seaman WE. PMID: 3871218.
-
[Not Available]. Immunol Today. 1984 Jul; 5(7):191-2. Wofsy D. PMID: 25289950.
-
Hormones, handedness, and autoimmunity. Immunol Today. 1984 Jun; 5(6):169-70. Wofsy D. PMID: 25289744.
-
The proliferating cells in autoimmune MRL/lpr mice lack L3T4, an antigen on "helper" T cells that is involved in the response to class II major histocompatibility antigens. J Immunol. 1984 Jun; 132(6):2686-9. Wofsy D, Hardy RR, Seaman WE. PMID: 6144707.
-
Monocytosis in the BXSB model for systemic lupus erythematosus. J Exp Med. 1984 Feb 01; 159(2):629-34. Wofsy D, Kerger CE, Seaman WE. PMID: 6363600; PMCID: PMC2187231.
-
Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. J Immunol. 1983 Apr; 130(4):1713-8. Seaman WE, Wofsy D, Greenspan JS, Ledbetter JA. PMID: 6187819.
-
Effects of castration and sex hormones on immune clearance and autoimmune disease in MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice. Clin Immunol Immunopathol. 1983 Mar; 26(3):361-9. Shear HL, Wofsy D, Talal N. PMID: 6872348.
-
Thymic influences on autoimmunity in MRL-lpr mice. Scand J Immunol. 1982 Jul; 16(1):51-8. Wofsy D, Ledbetter JA, Roubinian JR, Seaman WE, Talal N. PMID: 6981841.
-
Interleukin-2 deficiency, genes, and systemic lupus erythematosus. Arthritis Rheum. 1982 Jul; 25(7):838-42. Talal N, Dauphinee MJ, Wofsy D. PMID: 6285934.
-
Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol. 1981 Dec; 127(6):2483-7. Dauphinée MJ, Kipper SB, Wofsy D, Talal N. PMID: 6975325.
-
Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J Exp Med. 1981 Nov 01; 154(5):1671-80. Wofsy D, Murphy ED, Roths JB, Dauphinée MJ, Kipper SB, Talal N. PMID: 6975351; PMCID: PMC2186500.
-
Interleukin-2 deficiency in murine systemic lupus erythematosus. Trans Assoc Am Physicians. 1981; 94:341-8. Wofsy D, Dauphinée MJ, Kipper SB, Talal N. PMID: 6979821.
-
Culture-negative septic arthritis and bacterial endocarditis. Diagnosis by synovial biopsy. Arthritis Rheum. 1980 May; 23(5):605-7. Wofsy D. PMID: 6990934.
-
Coccidioidomycosis of the thyroid. Ann Intern Med. 1979 Sep; 91(3):409-11. Loeb JM, Livermore BM, Wofsy D. PMID: 475170.
US